Developer docs
API playgroundTry for free, no card

Search company profiles

Pranax

Full company profile

uuid0003ca8

Namestring
Pranax
Legal namestring
PranaX Corporation
Websiteurl
pranax.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

PranaX Corporation is a Houston, Texas-based private biotechnology company developing and commercializing regenerative biologics based on stem cell-derived exosomes (30–150 nm extracellular vesicles). The company's core technology is an exclusive patent license from MD Anderson Cancer Center covering exosome manufacturing, engineering, and non-cancer therapeutic applications, originally developed in a Phase I clinical trial for pancreatic cancer and validated as the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes, with safety data published in Nature Communications. PranaX operates a 7,400 sq ft FDA-registered, cGMP manufacturing facility with a cleanroom suite at the Levit Green life sciences district in the Texas Medical Center, giving it in-house production capacity that is uncommon among early-stage exosome competitors.

The company's product portfolio consists of stem cell-derived exosome products targeted at regenerative dermatology, aesthetic medicine, and healthspan/wellness applications rather than oncology indications. It sells through direct B2B enterprise field-sales relationships with physicians, aesthetic medicine practitioners, and wellness clinics, primarily in the Texas/USA market, with a secondary potential revenue stream from licensing its proprietary manufacturing IP. The company has invested in educational website content and earned-media channels (PRNewswire press releases, newsletter capture) to support physician engagement and stakeholder awareness.

PranaX is led by a C-suite built around exosome manufacturing expertise: CEO Phillip Maderia (formerly of Lonza, where he built Lonza's first 500L-scale GMP exosome process), Founder/COO Dr. Steven J. Greco, PhD (20+ years in stem cell biology), CFO Kenneth Klein, CMO Dr. Richard H. LeConey, MD (aesthetic-medicine pioneer), and Chief Business Officer Thad Johnson. The company has raised approximately $17M in an oversubscribed January 2026 Series A (plus an earlier $15M SEC Form D filing) from family offices, trusts, and individual biotech investors, with proceeds directed to GMP manufacturing scale-up, R&D, and commercialization.

Short descriptiontext

PranaX is a Houston-based biotechnology company that develops and commercializes stem cell-derived exosome regenerative biologics, licensed from MD Anderson Cancer Center and manufactured in its FDA-registered cGMP facility, sold B2B to aesthetic medicine practitioners and wellness clinics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome therapeutics, regenerative biologics, stem cell exosomes, aesthetic medicine, wellness biotechnology
Industry2 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Biologics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Exosome-Based Wellness Products
TypeOne Time License
Description

Sale of stem cell-derived exosome products for regenerative dermatology and wellness applications. Products are commercialized through B2B channels targeting healthcare providers and aesthetic medicine practitioners.

trysignalbase.com
2Licensing Royalties
TypeLicensing Royalties
Description

Technology licensed from MD Anderson Cancer Center provides access to core patent portfolio. Revenue may be generated through licensing of proprietary exosome technology.

pranax.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PranaX develops and commercializes proprietary stem cell-derived exosome products for regenerative medicine, wellness, and aesthetic applications. The company manufactures exosomes at an FDA-registered, cGMP facility in Houston, Texas, leveraging patented technology exclusively licensed from MD Anderson Cancer Center. Its exosome-based biologics are designed to support immune regulation, tissue regeneration, and neuronal communication for healthcare providers and aesthetic medicine practitioners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Safety demonstrated in FDA-approved clinical trial for exosome manufacturing technology
+1 more record
Product overview1 text field

PranaX is a biotechnology company offering a unified portfolio of exosome-based regenerative biologics for wellness and healthspan applications. The core offering consists of proprietary stem cell-derived exosome products and technologies, complemented by licensed manufacturing IP from MD Anderson Cancer Center. The company operates its own FDA-registered, cGMP manufacturing facility at the Levit Green life science campus in Houston, Texas. Products target aesthetic medicine, wellness, and healthy aging markets.

Product and service1 record
1Stem Cell-Derived Exosome Products
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

PranaX holds an exclusive technology license from MD Anderson Cancer Center. The license grants access to a core patent portfolio covering exosome manufacturing, engineering and pursuit of non-cancer therapeutic applications. The technology leverages the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korea-based company commercializing stem cell-derived exosome products for aesthetics, dermatology, and hair restoration. Closely comparable on product format (exosome topicals/injectables) and target customer (aesthetic medicine practitioners).

TypeDirect peer
Description

US aesthetics company offering platelet-derived and exosome-based regenerative products (PRP/exosome systems) to med-spas and aesthetic practices. Direct competitor in the physician-dispensed exosome aesthetics channel.

TypeDirect peer
Description

Clinical-stage biotech developing cell-derived extracellular vesicle and exosome-based therapeutics, with a pipeline overlapping MSC-derived biologics for inflammatory and regenerative indications.

TypeDirect peer
Description

UK-based biotech engineering exosomes for therapeutic delivery across rare disease and CNS indications. Highly comparable as a fellow developer of engineered exosome therapeutics with pharma partnerships.

5Codiak BioSciences (acquired by Lonza)
TypeBroad incumbent
Description

Pioneer in engineered exosome therapeutics; its IP was acquired by Lonza in 2023 after Codiak's closure. Lonza now offers commercial-scale exosome manufacturing services, directly competing with PranaX's manufacturing platform.

TypeDirect peer
Description

US biotech developing stem cell-derived extracellular vesicle therapies for regenerative medicine applications including aesthetics and wound healing. Comparable on MSC-exosome platform and clinical positioning.

TypeBroad incumbent
Description

Commercial-stage cell therapy company using mesenchymal lineage cell platforms for inflammatory and regenerative indications. Comparable on MSC-derived biologic modality and clinical pipeline breadth.

TypeEmerging player
Description

US-based lab producing MSC-derived exosome and growth factor products sold to physicians and clinics for aesthetic and regenerative applications. Direct overlap in the physician-channel exosome wellness segment.

TypeEmerging player
Description

US-based regenerative medicine company developing MSC-derived extracellular vesicle products (ExoFlo) for inflammatory conditions. Comparable as a peer-stage company selling MSC-derived EV biologics into physician channels.

10Pluristem Therapeutics
TypeBroad incumbent
Description

Cell therapy company developing placenta-derived MSC therapies for regenerative indications. Comparable on MSC-derived regenerative biologics platform and B2B hospital/physician commercialization model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pranax

Regenerative Biologicspranax.com

PranaX is a Houston-based biotechnology company that develops and commercializes stem cell-derived exosome regenerative biologics, licensed from MD Anderson Cancer Center and manufactured in its FDA-registered cGMP facility, sold B2B to aesthetic medicine practitioners and wellness clinics.

What Pranax does

PranaX Corporation is a Houston, Texas-based private biotechnology company developing and commercializing regenerative biologics based on stem cell-derived exosomes (30–150 nm extracellular vesicles). The company's core technology is an exclusive patent license from MD Anderson Cancer Center covering exosome manufacturing, engineering, and non-cancer therapeutic applications, originally developed in a Phase I clinical trial for pancreatic cancer and validated as the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes, with safety data published in Nature Communications. PranaX operates a 7,400 sq ft FDA-registered, cGMP manufacturing facility with a cleanroom suite at the Levit Green life sciences district in the Texas Medical Center, giving it in-house production capacity that is uncommon among early-stage exosome competitors.

The company's product portfolio consists of stem cell-derived exosome products targeted at regenerative dermatology, aesthetic medicine, and healthspan/wellness applications rather than oncology indications. It sells through direct B2B enterprise field-sales relationships with physicians, aesthetic medicine practitioners, and wellness clinics, primarily in the Texas/USA market, with a secondary potential revenue stream from licensing its proprietary manufacturing IP. The company has invested in educational website content and earned-media channels (PRNewswire press releases, newsletter capture) to support physician engagement and stakeholder awareness.

PranaX is led by a C-suite built around exosome manufacturing expertise: CEO Phillip Maderia (formerly of Lonza, where he built Lonza's first 500L-scale GMP exosome process), Founder/COO Dr. Steven J. Greco, PhD (20+ years in stem cell biology), CFO Kenneth Klein, CMO Dr. Richard H. LeConey, MD (aesthetic-medicine pioneer), and Chief Business Officer Thad Johnson. The company has raised approximately $17M in an oversubscribed January 2026 Series A (plus an earlier $15M SEC Form D filing) from family offices, trusts, and individual biotech investors, with proceeds directed to GMP manufacturing scale-up, R&D, and commercialization.

Pranax firmographics

Firmographics
Name
Pranax
Legal name
PranaX Corporation
Website
https://pranax.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
PranaX is a Houston-based biotechnology company that develops and commercializes stem cell-derived exosome regenerative biologics, licensed from MD Anderson Cancer Center and manufactured in its FDA-registered cGMP facility, sold B2B to aesthetic medicine practitioners and wellness clinics.
Ownership category
akta.pro rank

Pranax industry classification

Industry
Product category
Regenerative Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Exosome therapeutics
  • Regenerative biologics
  • Stem cell exosomes
  • Aesthetic medicine
  • Wellness biotechnology

Where Pranax is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pranax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Exosome-Based Wellness Products: Sale of stem cell-derived exosome products for regenerative dermatology and wellness applications. Products are commercialized through B2B channels targeting healthcare providers and aesthetic medicine practitioners.
  2. Licensing Royalties: Technology licensed from MD Anderson Cancer Center provides access to core patent portfolio. Revenue may be generated through licensing of proprietary exosome technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Pranax product offering

Product offering

Core offering

PranaX develops and commercializes proprietary stem cell-derived exosome products for regenerative medicine, wellness, and aesthetic applications. The company manufactures exosomes at an FDA-registered, cGMP facility in Houston, Texas, leveraging patented technology exclusively licensed from MD Anderson Cancer Center. Its exosome-based biologics are designed to support immune regulation, tissue regeneration, and neuronal communication for healthcare providers and aesthetic medicine practitioners.

Product overview

PranaX is a biotechnology company offering a unified portfolio of exosome-based regenerative biologics for wellness and healthspan applications. The core offering consists of proprietary stem cell-derived exosome products and technologies, complemented by licensed manufacturing IP from MD Anderson Cancer Center. The company operates its own FDA-registered, cGMP manufacturing facility at the Levit Green life science campus in Houston, Texas. Products target aesthetic medicine, wellness, and healthy aging markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stem Cell-Derived Exosome Products

Quantifiable outcome

  • Safety demonstrated in FDA-approved clinical trial for exosome manufacturing technology
  • +1 more outcomes

Companies that use Pranax

Customer profile

Segments2 records

Ideal customer profiles1 record

Pranax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pranax partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MD Anderson Cancer CentercoreTechnology or IntegrationPranaX holds an exclusive technology license from MD Anderson Cancer Center. The license grants access to a core patent portfolio covering exosome manufacturing, engineering and pursuit of non-cancer therapeutic applications. The technology leverages the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes.

Scale indicators3 records

Recent moves3 records

Expansion highlights5 records

Pranax competitors and assessment

Company assessment

Direct peers

  • ExoCoBio: Korea-based company commercializing stem cell-derived exosome products for aesthetics, dermatology, and hair restoration. Closely comparable on product format (exosome topicals/injectables) and target customer (aesthetic medicine practitioners).
  • Rion Aesthetics: US aesthetics company offering platelet-derived and exosome-based regenerative products (PRP/exosome systems) to med-spas and aesthetic practices. Direct competitor in the physician-dispensed exosome aesthetics channel.
  • Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle and exosome-based therapeutics, with a pipeline overlapping MSC-derived biologics for inflammatory and regenerative indications.
  • Evox Therapeutics: UK-based biotech engineering exosomes for therapeutic delivery across rare disease and CNS indications. Highly comparable as a fellow developer of engineered exosome therapeutics with pharma partnerships.
  • Aegle Therapeutics: US biotech developing stem cell-derived extracellular vesicle therapies for regenerative medicine applications including aesthetics and wound healing. Comparable on MSC-exosome platform and clinical positioning.

Broad incumbents

  • Codiak BioSciences (acquired by Lonza): Pioneer in engineered exosome therapeutics; its IP was acquired by Lonza in 2023 after Codiak's closure. Lonza now offers commercial-scale exosome manufacturing services, directly competing with PranaX's manufacturing platform.
  • Mesoblast: Commercial-stage cell therapy company using mesenchymal lineage cell platforms for inflammatory and regenerative indications. Comparable on MSC-derived biologic modality and clinical pipeline breadth.
  • Pluristem Therapeutics: Cell therapy company developing placenta-derived MSC therapies for regenerative indications. Comparable on MSC-derived regenerative biologics platform and B2B hospital/physician commercialization model.

Emerging players

  • Kimera Labs: US-based lab producing MSC-derived exosome and growth factor products sold to physicians and clinics for aesthetic and regenerative applications. Direct overlap in the physician-channel exosome wellness segment.
  • Direct Biologics: US-based regenerative medicine company developing MSC-derived extracellular vesicle products (ExoFlo) for inflammatory conditions. Comparable as a peer-stage company selling MSC-derived EV biologics into physician channels.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pranax social profiles

Digital presence

Pranax compliance and trust

Trust signal

Compliance1 record

Pranax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pranax leadership team

Management profile

Number of profiles

Profiles9 records

Pranax funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pranax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pranax

What does Pranax do?

PranaX develops and commercializes proprietary stem cell-derived exosome products for regenerative medicine, wellness, and aesthetic applications. The company manufactures exosomes at an FDA-registered, cGMP facility in Houston, Texas, leveraging patented technology exclusively licensed from MD Anderson Cancer Center. Its exosome-based biologics are designed to support immune regulation, tissue regeneration, and neuronal communication for healthcare providers and aesthetic medicine practitioners.

Is Pranax a public or private company?

Pranax is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pranax founded?

Pranax was founded in 2022. It employs 11 to 50 people.

Where is Pranax based?

Pranax is headquartered in Houston, United States, in the North America region.

How does Pranax make money?

Two revenue lines are on record. Exosome-Based Wellness Products are the primary driver. The others are licensing Royalties.

Who are Pranax's main competitors?

Direct peers on record are ExoCoBio, Rion Aesthetics, Capricor Therapeutics, Evox Therapeutics and Aegle Therapeutics. Broad incumbents are Codiak BioSciences (acquired by Lonza), Mesoblast and Pluristem Therapeutics. Emerging players are Kimera Labs and Direct Biologics.

Does Pranax have an API?

No public API is recorded for Pranax.

What industry is Pranax in?

Pranax's product category is Regenerative Biologics. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterPranaX appoints new chief medical officer to steer exosome strategyPranaX appointed Richard LeConey as chief medical officer to lead clinical development, physician engagement, and education for its exosome-based portfolio. The appointment reflects a shift toward structured clinical positioning as scrutiny of regenerative products intensifies.citybizPranaX Corporation Appoints Dr. Richard H. LeConey, MD as Chief Medical OfficerPranaX Corporation, a regenerative biotechnology company, announced the appointment of Dr. Richard H. LeConey, MD as Chief Medical Officer. Dr. LeConey, founder of AntiAge MedSpa in Houston, brings experience spanning emergency medicine, preventive care, and regenerative wellness to guide the strategic direction of the company's exosome product portfolio. The appointment is intended to support PranaX's expansion across the med spa and physician community and strengthen partnerships within the aesthetic and wellness sector.AijournPranaX Corporation Appoints Dr. Richard H. LeConey, MD as Chief Medical OfficerPranaX Corporation, a regenerative biotechnology company headquartered in Houston, Texas, announced the appointment of Dr. Richard H. LeConey, MD as its new Chief Medical Officer. Dr. LeConey brings experience spanning emergency medicine, preventive care, and regenerative wellness, having founded AntiAge MedSpa in Houston and earned his medical degree from the University of Texas Medical Branch at Galveston. In this role, he will oversee clinical development, physician education and engagement, and guide the strategic direction of the company's exosome product portfolio.PR NewswirePranaX Corporation Appoints Dr. Richard H. LeConey, MD as Chief Medical OfficerPranaX Corporation, a Houston-based regenerative biotechnology company, announced the appointment of Dr. Richard H. LeConey, MD as its new Chief Medical Officer. Dr. LeConey, founder of AntiAge MedSpa in Houston and a graduate of the University of Texas Medical Branch at Galveston, will oversee clinical development and guide the strategic direction of the company's exosome product portfolio. The company stated that his appointment will support its expansion across the med spa and physician community while advancing the adoption of regenerative biologics in aesthetic medicine and wellness.FinSMEsPranaX Raises $17M in Series A FundingPranaX Corporation, a Houston-based biotechnology company focused on regenerative biologics, raised $17M in Series A funding. The company will use the proceeds to advance R&D, expand its scientific and operational infrastructure, support strategic partnerships, and accelerate product development and commercialization of its stem cell-derived exosome-based wellness technologies. The funding positions the company to scale its manufacturing capabilities at its Levit Green life science campus in Houston, Texas.Longevity.TechnologyPranaX lands $17m to harness exosomes in regenerative biologicsUS biotech PranaX Corp has secured an oversubscribed $17 million Series A financing round to advance its development and commercialization of exosome-based regenerative biologics for healthspan and wellness applications. The company is built on technology licensed from The University of Texas MD Anderson Cancer Center, specifically patents spanning exosome manufacturing, engineering and therapeutic applications originally developed in a Phase I clinical trial for pancreatic cancer. The funding, backed by unnamed family offices, trusts and individual investors with biotech expertise, will be used to expand R&D, strengthen scientific and operational infrastructure, deepen strategic partnerships, and accelerate product commercialization.Pulse 2.0PranaX: $17 Million Series A Raised To Expand Exosome Based Regenerative Biologics PlatformPranaX closed an oversubscribed $17 million Series A financing led by family offices, trusts, and individual investors. The company will use the proceeds to advance research, expand infrastructure, and accelerate product development and commercialization of its exosome-based regenerative biologics platform.PR NewswirePranaX Corporation Closes $17 million Oversubscribed Series A RoundPranaX Corporation, a Houston-based regenerative biotechnology company focused on exosome-based technologies, has closed an oversubscribed $17 million Series A financing round led by family offices, trusts, and individual investors with expertise in biotechnology and regenerative medicine. The proceeds will be used to advance research and development initiatives, expand scientific and operational infrastructure, support strategic partnerships, and accelerate product development and commercialization efforts. The funding comes amid growing recognition of the exosome wellness sector as a promising frontier in regenerative medicine for healthy aging applications.SignalbasePranaX Secures $17M SeriesPranaX, a regenerative biological products company, has secured $17.0 million in a funding round to support its development of stem cell-derived exosome products for regenerative dermatology and wellness applications. The company holds an exclusive technology license from MD Anderson Cancer Center and operates its own FDA-registered, GMP manufacturing facility. PranaX plans to use the capital to accelerate R&D, scale production capabilities, and expand market penetration for its exosome-based products.Fastdata极数美国基于干细胞的外泌体研发商PranaX获得1700万美元A轮融资 – Fastdata极数PranaX, a U.S. biotechnology company developing stem cell-derived exosome products for regenerative healthcare, has completed a $17 million Series A funding round. The oversubscribed round was led by family offices, trust funds, and individual investors. The funding will support the company's continued development of evidence-based exosome therapies aimed at supporting human health.